Redx Pharma Plc (REDX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Redx Pharma Plc (REDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8193
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Redx Pharma Plc (Redx Pharma), formerly Redx Pharma Ltd is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s pipeline products include inhibitors for oncology and anti-infectives for treatment of diseases that include influenza and hepatitis B. Its proprietary redox switch is employed to generate novel antiviral and antibacterial drugs in the region of infectious disease. Redx Pharma’s redox switch is also used for delivering multiple development candidates over mechanistic approaches in the treatment of cancer. The company conducts research through its facilities in the UK. Redx Pharma is headquartered in Macclesfield, the UK.

Redx Pharma Plc (REDX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Redx Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Redx Pharma Acquires ROCK Inhibitor AMA0825 from Amakem 11
Partnerships 12
Horizon Discovery Enters into Research Agreement with Redx Pharma 12
Astrazeneca Enters into Research Agreement with Redx Pharma 13
Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 14
Licensing Agreements 15
Deinove Enters into Option and Licensing Agreement with Redx Pharma 15
Redx Pharma Enters Into Licensing Agreement With Pharmascience For Cancer Program 16
Dotmatics Enters Into Licensing Agreement With Redx Pharma 17
Redx Pharma Enters Into Licensing Agreement With Dishman For Prescription Drug Technology 18
Equity Offering 19
Redx Pharma to Raise USD15 Million in Private Placement of Shares 19
Redx Pharma to Raise USD3.6 Million in Rights Offering of Shares 21
Redx Pharma Raises USD14.2 Million in Private Placement of Shares 22
Redx Pharma Raises USD22.7 Million in IPO 23
Asset Transactions 24
Loxo Oncology Acquires BTK Inhibitor Program from Redx Pharma 24
Redx Pharma Plc – Key Competitors 25
Redx Pharma Plc – Key Employees 26
Redx Pharma Plc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
May 30, 2018: Redx Pharma: Interim results for the six months ended 31 March 2018 28
Dec 20, 2017: Redx Pharma: Final Results for the Year Ended 30 September 2017 31
May 17, 2017: Redx Pharma: Interim Results for the six months ended 31 March 2017 33
Mar 21, 2017: Redx Pharma Announces Final results for the year ended 30 September 2016 34
Corporate Communications 35
Jun 04, 2018: REDX PHARMA: Directorate Update 35
Jun 04, 2018: Redx Pharma Appoints Lisa Anson As Chief Executive Officer 36
Aug 14, 2017: Redx announces the resignation of Non-Executive Director David Lawrence 37
Apr 20, 2017: Redx Pharma: Appointment of Chairman 38
Legal and Regulatory 39
Oct 27, 2017: Redx Pharma: Update on Application to the High Court 39
Government and Public Interest 40
Mar 30, 2017: Redx Pharma awarded US$1 million grant by CARB-X 40
Product News 41
08/31/2017: Redx to present new scientific data at ESMO 2017 41
06/23/2017: Redx announces MHRA approval of its Clinical Trial Application for Porcupine Inhibitor RXC004 42
01/27/2017: Redx outlines growing opportunity for Porcupine inhibitors 43
01/22/2018: Redx Pharma Announces Appointment of Experienced Drug Development Clinician as Chief Medical Officer 44
Clinical Trials 45
Jan 22, 2018: Redx Pharma appoints chief medical officer who will oversee launch of phase I clinical trial of new cancer drug 45
Other Significant Developments 46
Nov 06, 2017: Redx Provides a Strategic Update and Announces that Trading is to recommence in its Shares 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Redx Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Redx Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Redx Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Redx Pharma Acquires ROCK Inhibitor AMA0825 from Amakem 11
Horizon Discovery Enters into Research Agreement with Redx Pharma 12
Astrazeneca Enters into Research Agreement with Redx Pharma 13
Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 14
Deinove Enters into Option and Licensing Agreement with Redx Pharma 15
Redx Pharma Enters Into Licensing Agreement With Pharmascience For Cancer Program 16
Dotmatics Enters Into Licensing Agreement With Redx Pharma 17
Redx Pharma Enters Into Licensing Agreement With Dishman For Prescription Drug Technology 18
Redx Pharma to Raise USD15 Million in Private Placement of Shares 19
Redx Pharma to Raise USD3.6 Million in Rights Offering of Shares 21
Redx Pharma Raises USD14.2 Million in Private Placement of Shares 22
Redx Pharma Raises USD22.7 Million in IPO 23
Loxo Oncology Acquires BTK Inhibitor Program from Redx Pharma 24
Redx Pharma Plc, Key Competitors 25
Redx Pharma Plc, Key Employees 26
Redx Pharma Plc, Subsidiaries 27

List of Figures
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Redx Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Redx Pharma Plc (REDX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Prolung Inc (LUNG):医療機器:M&Aディール及び事業提携情報
    Summary Prolung Inc(Prolung) formerly known as Fresh Medical Laboratories Inc, is a medical device company that offers diagnostic services. The company offers electro pulmonary nodule scanner system used for the non invasive early diagnostics of different types of diseases. Its EPN system consists o …
  • Littelfuse, Inc.:企業のM&A・事業提携・投資動向
    Littelfuse, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Littelfuse, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Akers Biosciences Inc (AKER):医療機器:M&Aディール及び事業提携情報
    Summary Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. Its products include BreathScan alcohol detectors, CHUBE, METRO …
  • Earle M. Jorgensen Company:企業の戦略・SWOT・財務情報
    Earle M. Jorgensen Company - Strategy, SWOT and Corporate Finance Report Summary Earle M. Jorgensen Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Knight Therapeutics Inc (GUD):医療機器:M&Aディール及び事業提携情報
    Summary Knight Therapeutics Inc (Knight Therapeutics) is a specialty pharmaceutical company focused on acquisition, licensing, marketing and distribution of prescription, consumer health products and medical devices. Its consumer health products are used in the treatment of metabolic diseases, derma …
  • Black Hills Power Inc:電力:M&Aディール及び事業提携情報
    Summary Black Hills Power Inc (Black Hills), a subsidiary of Black Hills Corp, is a power company that generates, transmits and distributes electricity. The company generates electricity through coal, gas, and oil resources. Its services include electricity and natural gas transmission and distribut …
  • Public Power Corporation S.A.:企業の戦略・SWOT・財務情報
    Public Power Corporation S.A. - Strategy, SWOT and Corporate Finance Report Summary Public Power Corporation S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Cardinal Health, Inc.:企業の戦略・SWOT・財務情報
    Cardinal Health, Inc. - Strategy, SWOT and Corporate Finance Report Summary Cardinal Health, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Baloise Belgium NV:企業の戦略・SWOT・財務分析
    Baloise Belgium NV - Strategy, SWOT and Corporate Finance Report Summary Baloise Belgium NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • RadNet Inc (RDNT):医療機器:M&Aディール及び事業提携情報
    Summary RadNet Inc (RadNet) is a radiology company which specializes in diagnostic imaging services. The company offers freestanding, fixed-site diagnostic imaging services including imaging procedures magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nu …
  • Sopheon Plc:企業の戦略・SWOT・財務情報
    Sopheon Plc - Strategy, SWOT and Corporate Finance Report Summary Sopheon Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • HSBC Trinkaus & Burkhardt Private Banking:企業の戦略・SWOT・財務情報
    HSBC Trinkaus & Burkhardt Private Banking - Strategy, SWOT and Corporate Finance Report Summary HSBC Trinkaus & Burkhardt Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Damen Shipyards Group:企業の戦略・SWOT・財務情報
    Damen Shipyards Group - Strategy, SWOT and Corporate Finance Report Summary Damen Shipyards Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • China National Petroleum Corp:企業の戦略的SWOT分析
    China National Petroleum Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • BioView Ltd (BIOV)-医療機器分野:企業M&A・提携分析
    Summary BioView Ltd (BioView) is a medical device company that develops, manufactures and markets automated cell imaging and analysis solutions, which incorporate proprietary imaging, analysis and review technology. The technology provides automatic control of fully motorized fluorescent and bright- …
  • Mondelez International Inc (MDLZ):企業の財務・戦略的SWOT分析
    Mondelez International Inc (MDLZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • FLIR Systems Inc:企業の戦略・SWOT・財務情報
    FLIR Systems Inc - Strategy, SWOT and Corporate Finance Report Summary FLIR Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Corcept Therapeutics Inc (CORT):製薬・医療:M&Aディール及び事業提携情報
    Summary Corcept Therapeutics Inc (Corcept) is a research focused pharmaceutical company which discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company focuses on developing drugs for the treatment of severe metabolic, oncologic an …
  • Hyperion Insurance Group Ltd:企業の戦略・SWOT・財務情報
    Hyperion Insurance Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Hyperion Insurance Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Finder Exploration Pty Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Finder Exploration Pty Ltd (Finder) is an oil and gas company that acquires and explores prospective acreage. The company offers acquisition of prospective acreage through drilling and detailed assessment and risk mitigation of exploration acreage. It holds exploration operations in Bedout S …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆